necrosis/fever

BACKGROUND OF THE INVENTION The invention set forth in this specification pertains to a new and improved method and apparatus for causing necrosis of neoplasm by hyperthermia. Aberrant cells within the body, such as are frequently referred to as neoplasm, are the subject of a great deal of concern

CROSS REFERENCE TO RELATED APPLICATIONS This application contains subject matter set forth in the co-pending U.S.A. application by the inventor named herein, Dr. Robert Rand et al., Ser. No. 223,727 filed Jan. 9, 1981 entitled "Induction Heating Method For Use In Causing Necrosis of Neoplasm" now

BACKGROUND OF THE INVENTION This invention is directed to a process of necrosing neoplasms as a result of hyperthermia of the neoplasm induced by hysteresis heating at selected frequencies of particles associated with the neoplasm. It is a recognized medical fact that certain surgical invasions of

BACKGROUND OF THE INVENTION Release of such cytokines as tumor necrosis factor a (TNF-.alpha.) and transforming growth factor .alpha. (TGF-.alpha.) can cause adverse reactions ranging from psoriasis to sepsis. Many of these reactions are related to inflammation or autoimmune conditions, such as

FIELD OF THE INVENTION The present invention relates to a specialized method for whole-body hyperthermia, including extracorporeal blood heating and dialysis, as an antiviral protocol. BACKGROUND OF THE INVENTION Hyperthermia as a treatment of tumors has been carefully studied and applied since the

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

BACKGROUND OF THE INVENTION The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)

FIELD OF THE INVENTION Embodiments of the present invention are generally related to apparatus and methodology of thermal applicators in cancer therapy. In particular, the present embodiments are directed to a technique called "nanoparticle ferromagnetic resonance heating," where ferromagnetic

BACKGROUND OF THE INVENTION Release of such cytokines as tumor necrosis factor .alpha.(TNF-.alpha.) and transforming growth factor .alpha.(TGF-.alpha.) can cause adverse reactions ranging from fever to sepsis. Many of these reactions are related to inflammation or autoinmuune conditions, such as

BACKGROUND 1. Field of the Invention The invention relates to methods of using interleukin-1 (IL-1) antagonists to treat autoinflammatory diseases, such as, for example, including familial mediterranean fever (FMF), NOMID/CINCA, Muckle-Wells Syndrome, FCAS, and tumour necrosis factor

BACKGROUND 1. Field of the Invention The invention relates to methods of using interleukin-1 (IL-1) antagonists to treat autoinflammatory diseases, such as, for example, including familial mediterranean fever (FMF), NOMID/CINCA, Muckle-Wells Syndrome, FCAS, and tumor necrosis factor